1. Home
  2. LGO vs TTRX Comparison

LGO vs TTRX Comparison

Compare LGO & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LGO

Largo Inc.

HOLD

Current Price

$0.78

Market Cap

104.6M

Sector

N/A

ML Signal

HOLD

TTRX

Turn Therapeutics Inc.

HOLD

Current Price

$6.13

Market Cap

107.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGO
TTRX
Founded
1988
2015
Country
Canada
United States
Employees
N/A
2
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
104.6M
107.2M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
LGO
TTRX
Price
$0.78
$6.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$3.25
$8.00
AVG Volume (30 Days)
732.3K
61.7K
Earning Date
05-12-2026
05-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$50.56
N/A
Revenue Next Year
$59.94
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.75
$2.57
52 Week High
$2.70
$6.75

Technical Indicators

Market Signals
Indicator
LGO
TTRX
Relative Strength Index (RSI) 33.83 63.59
Support Level N/A $4.09
Resistance Level $1.26 $6.75
Average True Range (ATR) 0.06 0.62
MACD 0.00 0.01
Stochastic Oscillator 26.00 72.48

Price Performance

Historical Comparison
LGO
TTRX

About LGO Largo Inc.

Largo Inc is committed to the production and supply of high-quality vanadium products. The company is also focused on the advancement of renewable energy storage solutions through Largo Clean Energy and its vanadium redox flow battery technology. The Company is engaged in the mining, exploration, and development of mineral properties, predominantly in Brazil, through which it produces and supplies vanadium products VPURE Flake, VPURE+ Flake, and VPURE+ Powder. The company has operating segments: sales & trading, mine properties, which generates key revenue, corporate, exploration and evaluation properties, Clean Energy, and Largo Physical Vanadium.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: